Royce & Associates LP Has $3.14 Million Stake in Palvella Therapeutics, Inc. $PVLA

Royce & Associates LP decreased its position in Palvella Therapeutics, Inc. (NASDAQ:PVLA) by 39.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,010 shares of the company’s stock after selling 19,499 shares during the period. Royce & Associates LP owned approximately 0.25% of Palvella Therapeutics worth $3,141,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Russell Investments Group Ltd. acquired a new position in Palvella Therapeutics in the third quarter valued at $36,000. China Universal Asset Management Co. Ltd. acquired a new position in Palvella Therapeutics in the fourth quarter valued at $167,000. Chung Wu Investment Group LLC lifted its holdings in Palvella Therapeutics by 1,200.0% in the fourth quarter. Chung Wu Investment Group LLC now owns 2,600 shares of the company’s stock valued at $272,000 after buying an additional 2,400 shares during the period. AlphaQuest LLC acquired a new position in Palvella Therapeutics in the third quarter valued at $164,000. Finally, SG Americas Securities LLC acquired a new position in Palvella Therapeutics in the fourth quarter valued at $281,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Insiders Place Their Bets

In related news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total transaction of $507,592.98. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 20.50% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on PVLA shares. Stephens restated an “overweight” rating and issued a $220.00 target price on shares of Palvella Therapeutics in a report on Thursday, May 21st. Chardan Capital restated a “buy” rating and issued a $240.00 target price on shares of Palvella Therapeutics in a report on Thursday, May 21st. HC Wainwright lifted their price target on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Stifel Nicolaus set a $250.00 price target on shares of Palvella Therapeutics in a research note on Tuesday, February 24th. Finally, Truist Financial set a $210.00 target price on shares of Palvella Therapeutics in a research report on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Palvella Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $199.53.

Palvella Therapeutics Stock Performance

Palvella Therapeutics stock opened at $118.46 on Friday. Palvella Therapeutics, Inc. has a fifty-two week low of $20.20 and a fifty-two week high of $151.18. The stock has a market cap of $1.70 billion, a PE ratio of -28.41 and a beta of -0.13. The firm’s 50-day simple moving average is $121.17 and its 200 day simple moving average is $106.84.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.30). As a group, analysts predict that Palvella Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.